Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan or irinotecan liposomes plus oxaliplatin and bevacizumab in advanced colorectal cancer after failure of standard second-line therapy
ChiCTR2600126499Phase 2Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Jun 2026
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan and irinotecan liposome in colorectal adenocarcinoma (2 arms), sponsored by Shanghai East Hospital. Primary endpoint: Progression-Free Survival (PFS). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
irinotecanirinotecan liposome
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600126499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126499.